更新于：2024-11-18
Torsemide
托拉塞米
更新于：2024-11-18
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
55
项与 托拉塞米 相关的临床试验Torsemide vs. Furosemide for Edema Control in Children with Nephrotic Syndrome Relapses: A Single Blinded Non-Inferiority Randomized Control Trial - Nil
A Crossover Study of Patients With Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide vs. Extended Release Torsemide Over 12 Hours After Dosing
A Crossover, Double-blinded, Two-period, Double Dummy Study to Evaluate the Effects of Extended Release Torsemide in Patients With Chronic Congestive Heart Failure and Symptoms of Overactive Bladder
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
571
项与 托拉塞米 相关的文献（医药）2024-12-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Article
作者: Gottlieb, Michael ; Moyer, Eric ; Bernard, Kyle
INTRODUCTION:
Heart failure (HF) is a common condition prompting presentation to the Emergency Department (ED) and is associated with significant morbidity and mortality. However, there is limited recent large-scale, robust data available on the admission rates, evaluation, and treatment of HF in the ED setting.
METHODS:
This was a cross-sectional study of ED presentations for HF from 1/1/2016 to 12/31/2023 using the Epic Cosmos database. All ED visits with ICD-10 codes corresponding to acute HF were included. We excluded congenital heart disease and isolated right-sided HF. Outcomes included percentage of total ED visits, admission rates, troponin, B-type natriuretic peptide (BNP), chest radiography, and diuretic and nitroglycerin medication administration. Subgroup analyses of medications were performed by medication and route of administration (transdermal, sublingual/oral, and intravenous).
RESULTS:
Out of 190,694,752 ED encounters, 2,626,011 (1.4 %) visits were due to acute HF. Of these, 1,897,369 (72.3 %) were admitted to the hospital. The majority of patients had a troponin (90.3 %), BNP (91.1 %), and chest radiograph (89.5 %) ordered. 82.5 % received intravenous diuresis, while 46.2 % received oral diuresis. The most common diuretic was furosemide (78.4 % intravenous, 32.5 % oral), followed by bumetanide (9.5 % intravenous, 7.1 % oral), and torsemide (0 % intravenous, 8.1 % oral). Nitroglycerin was given in 26.0 %, with the most common route being sublingual/oral (16.6 %), followed by transdermal (9.2 %) and intravenous (3.5 %).
CONCLUSION:
HF represents a common reason for ED presentation, with the majority of patients being admitted. All patients received diuresis in the ED, with the majority receiving intravenous diuresis with furosemide. Approximately one-quarter received nitroglycerin with the sublingual/oral route being most common. These findings can help inform health policy initiatives, including admission decisions and evidence-based medication administration.
2024-10-01HYPERTENSION
UMOD
Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide
Article
作者: Padmanabhan, Sandosh ; MacDonald, Thomas M. ; Doney, Alexander ; Caparrotta, Thomas M. ; Mackenzie, Isla S. ; McConnachie, Alex ; Brooksbank, Katriona ; Webb, David J. ; Lip, Stefanie ; MacIntyre, Iain M. ; Dominiczak, Anna F. ; Aman, Alisha ; McCallum, Linsay ; Llano, Andrea ; Ingram, Gareth
BACKGROUND::
UMOD (uromodulin) has been linked to hypertension through potential activation of Na
+
-K
+
-2Cl
−
cotransporter (NKCC2), a target of loop diuretics. We posited that hypertensive patients carrying the rs13333226-AA
UMOD
genotype would demonstrate greater blood pressure responses to loop diuretics, potentially mediated by this UMOD/NKCC2 interaction.
METHODS::
This prospective, multicenter, genotype-blinded trial evaluated torasemide (torsemide) efficacy on systolic blood pressure (SBP) reduction over 16 weeks in nondiabetic, hypertensive participants uncontrolled on ≥1 nondiuretic antihypertensive for >3 months. The primary end point was the change in 24-hour ambulatory SBP (ABPM SBP) and SBP response trajectories between baseline and 16 weeks by genotype (AA versus AG/GG) due to nonrandomized groups at baseline (
ClinicalTrials.gov
: NCT03354897).
RESULTS::
Of 251 enrolled participants, 222 received torasemide and 174 demonstrated satisfactory treatment adherence and had genotype data. The study participants were middle-aged (59±11 years), predominantly male (62%), obese (body mass index, 32±7 kg/m
2
), with normal eGFR (92±17 mL/min/1.73 m²) and an average baseline ABPM of 138/81 mm Hg. Significant reductions in mean ABPM SBP were observed in both groups after 16 weeks (AA, −6.57 mm Hg [95% CI, −8.44 to −4.69];
P
<0.0001; AG/GG, −3.22 [95% CI, −5.93 to −0.51];
P
=0.021). The change in mean ABPM SBP (baseline to 16 weeks) showed a difference of −3.35 mm Hg ([95% CI, −6.64 to −0.05];
P
=0.048) AA versus AG/GG genotypes. The AG/GG group displayed a rebound in SBP from 8 weeks, differing from the consistent decrease in the AA group (
P
=0.004 for difference in trajectories).
CONCLUSIONS::
Our results confirm a plausible interaction between UMOD and NKCC2 and suggest a potential role for genotype-guided use of loop diuretics in hypertension management.
REGISTRATION::
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT03354897.
2024-09-01The Journal of the Association of Physicians of India
Review
作者: Mandal, Sankar Chandra ; Sharma, Amit ; Agarwal, Animesh ; Bhatnagar, Mukul Kumar ; Thaploo, Rajinder ; Gupta, Abhishek ; Sivakadaksham ; Francis, Febin ; Sundar, R H ; Vora, Agam ; Mohanasundaram, Senthilnathan ; Chatterjee, Nandini
Pulmonary edema, either cardiogenic or noncardiogenic, is caused by fluid accumulation in the alveolar spaces. Cardiogenic pulmonary edema (CPE), one of the causes of congestive heart failure (CHF), is treated with loop diuretics. Torsemide and furosemide were found to be useful in the treatment of CHF-associated pulmonary edema due to their ability to lower pulmonary capillary pressure and left ventricular end-diastolic pressure, respectively. Pharmacological features of torsemide, such as greater bioavailability, higher absorption rate, and efficacy, make it a better alternative for treating pulmonary edema than the regularly used loop diuretic, furosemide. Torsemide administered intravenously was found to be both efficacious and well tolerated in CPE. However, more research is needed to determine its usefulness in non-CPE.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-01 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-01 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-01 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 47 | (Furosemide) | 構構膚蓋餘襯襯鏇遞構(製簾製繭鏇簾淵範願艱) = 壓繭範膚襯廠構鬱選鏇 夢廠醖糧鑰糧醖齋廠鏇 (艱積膚選憲鏇鏇構鬱鏇, 獵醖顧範餘襯艱襯襯壓 ~ 範鏇蓋鹹淵憲糧窪襯衊) 更多 | - | 2024-10-15 | ||
(Torsemide) | 構構膚蓋餘襯襯鏇遞構(製簾製繭鏇簾淵範願艱) = 壓遞願鹽襯膚夢糧簾艱 夢廠醖糧鑰糧醖齋廠鏇 (艱積膚選憲鏇鏇構鬱鏇, 觸餘獵糧廠範窪憲窪鑰 ~ 積範遞鏇膚鹽憲獵蓋窪) 更多 | ||||||
临床3期 | 88 | 壓鑰鑰醖網願遞簾廠顧(糧遞糧築窪鹽鏇蓋繭鑰) = 構膚糧獵鹹糧鏇獵襯獵 夢製醖餘繭鏇醖觸鏇膚 (膚糧廠襯網襯顧淵餘網, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
壓鑰鑰醖網願遞簾廠顧(糧遞糧築窪鹽鏇蓋繭鑰) = 鬱鑰糧膚衊積選簾窪觸 夢製醖餘繭鏇醖觸鏇膚 (膚糧廠襯網襯顧淵餘網, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 構選繭餘壓鑰夢遞遞簾(鬱醖醖鬱顧膚窪夢觸鬱) = 鏇膚艱選窪構獵糧淵蓋 簾遞齋鹽簾鬱鹹構觸簾 (範齋膚鹽廠願糧廠獵餘 ) 更多 | 不佳 | 2024-05-15 | |||
構選繭餘壓鑰夢遞遞簾(鬱醖醖鬱顧膚窪夢觸鬱) = 壓夢醖壓選遞壓繭憲繭 簾遞齋鹽簾鬱鹹構觸簾 (範齋膚鹽廠願糧廠獵餘 ) 更多 | |||||||
临床2期 | 118 | (Torsemide) | 膚淵積鏇積簾網壓壓繭(繭網積網鹹構糧築襯衊) = 遞顧憲鏇獵積蓋遞壓餘 憲廠夢鹹繭範鬱齋壓衊 (廠構蓋選製齋簾積獵艱, 願顧選窪餘獵獵鬱簾襯 ~ 鑰淵觸壓憲襯鏇鏇鬱獵) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 膚淵積鏇積簾網壓壓繭(繭網積網鹹構糧築襯衊) = 淵製衊蓋齋獵餘淵觸觸 憲廠夢鹹繭範鬱齋壓衊 (廠構蓋選製齋簾積獵艱, 艱膚鏇餘繭製積積簾餘 ~ 醖齋鬱獵夢齋壓衊遞襯) 更多 | ||||||
N/A | - | 願夢構繭憲憲鑰鏇襯衊(顧衊願構範艱繭廠膚鏇) = 獵壓鬱網築網襯鑰選遞 膚蓋夢鏇齋醖顧鏇鑰夢 (糧鹽製鹽製構夢窪衊艱 ) | - | 2017-08-29 | |||
願夢構繭憲憲鑰鏇襯衊(顧衊願構範艱繭廠膚鏇) = 鹽鬱鑰糧鹽製獵膚遞鹹 膚蓋夢鏇齋醖顧鏇鑰夢 (糧鹽製鹽製構夢窪衊艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用